2. Academic Validation
  3. Non-Hodgkin's lymphomas, version 4.2014

Non-Hodgkin's lymphomas, version 4.2014

  • J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303. doi: 10.6004/jnccn.2014.0125.
Andrew D Zelenetz,  Leo I Gordon,  William G Wierda,  Jeremy S Abramson,  Ranjana H Advani,  C Babis Andreadis,  Nancy Bartlett,  John C Byrd,  Myron S Czuczman,  Luis E Fayad,  Richard I Fisher,  Martha J Glenn,  Nancy Lee Harris,  Richard T Hoppe,  Steven M Horwitz,  Christopher R Kelsey,  Youn H Kim,  Susan Krivacic,  Ann S LaCasce,  Auayporn Nademanee,  Pierluigi Porcu,  Oliver Press,  Rachel Rabinovitch,  Nishitha Reddy,  Erin Reid,  Ayman A Saad,  Lubomir Sokol,  Lode J Swinnen,  Christina Tsien,  Julie M Vose,  Joachim Yahalom,  Nadeem Zafar,  Mary Dwyer,  Hema Sundar,  National comprehensive cancer network
PMID: 25190696 DOI: 10.6004/jnccn.2014.0125
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Figures